MIRM - Mirum Pharmaceuticals company's preliminary unaudited financial results for Q1 2023
2023-04-12 09:20:49 ET
- Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q1 Revenue of $31.5M.
- Approximately $232.1 million of cash, cash equivalents, restricted cash equivalents and short?term investments as of March 31, 2023;
- These are all company’s preliminary unaudited financial results for the first quarter of 2023
For further details see:
Mirum Pharmaceuticals company’s preliminary unaudited financial results for Q1 2023